Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.30 - $346.85
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.84M
Market Cap
$156.11B
Enterprise Value$204.68B
Total Cash (Recent Filing)$8.81B
Total Debt (Recent Filing)$57.38B
Price to Earnings (P/E)26.5
Beta0.38
Next Earnings
Aug 05, 2025EPS Estimate
5.23Last Dividend Ex-Date
May 16, 2025Dividend Yield3.19%
Share Statistics
EPS (TTM)4.90
Shares Outstanding537,706,100
10 Day Avg. Volume2,659,513
30 Day Avg. Volume2,835,049
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)25.16
Price to Sales (P/S)0.00
P/FCF Ratio14.30
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue1.56
Enterprise Value/Gross Profit9.52
Enterprise Value/Ebitda4.18
Forecast
1Y Price Target
$326.18Price Target Upside12.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Amgen News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessImdelltra (tarlatamab) demonstrated a 40% reduction in the risk of death and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with SCLC who progressed after one line of platinum-based chemotherapy.
Financial PerformanceAmgen delivers strong FY24 performance with 19% revenue growth, showcasing the company's robust financial health and potential for future growth.
Product Launch And Market CaptureAmgen excels in being the first wave of biosimilars to launch in the market, capturing a large portion of market shares and providing a steady stream of income.
Bears Say
Biosimilar CompetitionAMGN anticipates sales erosion from biosimilar competition in the second half of the year.
Patent Expiration RiskAmgen's drug portfolio faces the risk of patent expiration in the coming years, which could lead to increased competition from generic versions.
Potential Revenue DeclineRevenue and EPS forecasts for 2026 and beyond are expected to be moderately lower due to increased R&D spending and potential generic erosion.
Ownership Overview
0.19% Insiders
23.54% Mutual Funds
20.51% Other Institutional Investors
28.07% Public Companies and Individual Investors
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $156.11B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Aug 05, 2025 which is in 57 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on May 01, 2025. The company reported $4.9 earnings per share for the quarter, beating the consensus estimate of $4.27 by $0.63.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.19%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.23.
How many shares outstanding does Amgen have?
Amgen has 537,706,100 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.9 in its last earnings report, beating expectations of $4.27. Following the earnings report the stock price went down -0.899%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$326.18 (12.35% Upside)
$326.18 (12.35% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 86%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 595.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.96%
12-Months-Change
Fundamentals
Return on Equity
105.67%
Trailing 12-Months
Asset Growth
-3.89%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with notable revenue and volume growth, successful biosimilar launches, and strategic expansions. However, there are concerns regarding potential impacts from tariffs and tax uncertainties, as well as challenges in maintaining inventory levels in the rare disease segment.Read More>AMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$326.18
▲(12.35%Upside)